Select Journal or Resource JAMA & Archives Home JAMA Archives of   Dermatology   Facial Plastic Surgery   Family Medicine (1992-2000)   General Psychiatry   Internal Medicine   Neurology   Neurology and Psychiatry (1919-1959)   Ophthalmology   Otolaryngology—Head & Neck Surgery   Pediatrics & Adolescent Medicine   Surgery JAMA-français JAMA & Archives CME Calendar of Events JAMA Career Center For The Media JAMAevidence Peer Review Congress Student JAMA (1998-2004)

	Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In Vol. 9 No. 2, February 2000   Archives  •  Online Features Original Contribution  This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (111)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal Orlistat in the Long-term Treatment of Obesity in Primary Care Settings Jonathan Hauptman, MD; Charles Lucas, MD; Mark N. Boldrin, MS; Harry Collins, MD Karen R. Segal, PhD Arch Fam Med. 2000;9:160-167. Objective  To evaluate the long-term efficacy and tolerability within primary care settings of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity. Design  Randomized, double-blind, placebo-controlled, multicenter study. Participants  A group of 796 obese patients (body mass index, 30-44 kg/m2), treated with placebo 3 times a day (TID), 60 mg of orlistat TID, or 120 mg of orlistat TID, in conjunction with a reduced-energy diet for the first year and a weight-maintenance diet during the second year. Setting  Seventeen primary care centers in the United States. Main Outcome Measures  Changes in body weight and obesity-related disease risk factors. Results  Patients treated with orlistat lost significantly more weight (7.08 ± 0.54 and 7.94 ± 0.57 kg for the 60-mg and 120-mg orlistat groups, respectively) than those treated with placebo (4.14 ± 0.56 kg) in year 1 (P<.001) and sustained more of this weight loss during year 2 (P<.001). More patients treated with orlistat lost 5% or more of their initial weight in year 1 (48.8% and 50.5% of patients in the 60-mg and 120-mg groups, respectively) compared with placebo (30.7%; P<.001), and approximately 34% of patients in the orlistat groups sustained weight loss of 5% or greater over 2 years compared with 24% in the placebo group (P<.001). Orlistat produced greater improvements than placebo in serum lipid levels and blood pressure and was well tolerated, although treatment resulted in a higher incidence of gastrointestinal events. Conclusions  This long-term study indicates that orlistat is an effective adjunct to dietary intervention in the treatment of obesity in primary care settings. for the Orlistat Primary Care Study Group From Departments of International Clinical Research (Dr Hauptman and Mr Boldrin) and Medical Affairs (Drs Lucas and Segal), Hoffman–LaRoche Inc, Nutley, NJ; and the Edison Medical Group, Edison, NJ (Dr Collins). RELATED ARTICLE The Archives of Family Medicine Continuing Medical Education Program Arch Fam Med. 2000;9(2):175-177. FULL TEXT   THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES Over-the-counter weight loss with orlistat? DTB 2009;47:125-127. ABSTRACT | FULL TEXT   Differences between human subjects in the composition of the faecal bacterial community and faecal metabolism of linoleic acid Devillard et al. Microbiology 2009;155:513-520. ABSTRACT | FULL TEXT   Mechanism of conjugated linoleic acid and vaccenic acid formation in human faecal suspensions and pure cultures of intestinal bacteria McIntosh et al. Microbiology 2009;155:285-294. ABSTRACT | FULL TEXT   REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns Elangbam Vet Pathol 2009;46:10-24. ABSTRACT | FULL TEXT   Review: Pharmacotherapy as part of a weight management programme: a UK perspective Barnett British Journal of Diabetes & Vascular Disease 2007;7:268-277. ABSTRACT   State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant Dunican et al. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:367-388. ABSTRACT   Pharmacotherapeutic Options for Overweight Adolescents Dunican et al. The Annals of Pharmacotherapy 2007;41:1445-1455. ABSTRACT | FULL TEXT   Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity Patel and Pathak Am J Health Syst Pharm 2007;64:481-489. ABSTRACT | FULL TEXT   Pharmacologic Treatment Options for Obesity: Current and Potential Medications Fujioka and Lee Nutr Clin Pract 2007;22:50-54. ABSTRACT | FULL TEXT   Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial Anderson et al. The Annals of Pharmacotherapy 2006;40:1717-1723. ABSTRACT | FULL TEXT   Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks Gadde and Allison Circulation 2006;114:974-984. FULL TEXT   Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society Villareal et al. Am. J. Clin. Nutr. 2005;82:923-934. ABSTRACT | FULL TEXT   A Comparison of Meal Replacements and Medication in Weight Maintenance after Weight Loss LeCheminant et al. J. Am. Coll. Nutr. 2005;24:347-353. ABSTRACT | FULL TEXT   Use And Costs Of Bariatric Surgery And Prescription Weight-Loss Medications Encinosa et al. Health Aff (Millwood) 2005;24:1039-1046. ABSTRACT | FULL TEXT   Effects of Weight Loss in Overweight/Obese Individuals and Long-Term Hypertension Outcomes: A Systematic Review Aucott et al. Hypertension 2005;45:1035-1041. ABSTRACT | FULL TEXT   Meta-Analysis: Pharmacologic Treatment of Obesity Li et al. ANN INTERN MED 2005;142:532-546. ABSTRACT | FULL TEXT   Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials Hutton and Fergusson Am. J. Clin. Nutr. 2004;80:1461-1468. ABSTRACT | FULL TEXT   Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation Klein et al. Circulation 2004;110:2952-2967. ABSTRACT | FULL TEXT   Diagnosis and Treatment of Obesity in Adults: An Applied Evidence-Based Review Orzano and Scott J Am Board Fam Med 2004;17:359-369. ABSTRACT | FULL TEXT   Screening and Interventions for Obesity in Adults: Summary of the Evidence for the U.S. Preventive Services Task Force McTigue et al. ANN INTERN MED 2003;139:933-949. ABSTRACT | FULL TEXT   Anesthetic Considerations for Bariatric Surgery Ogunnaike et al. Anesth. Analg. 2002;95:1793-1805. FULL TEXT   Effects of Obesity Surgery on Non-Insulin-Dependent Diabetes Mellitus Greenway et al. Arch Surg 2002;137:1109-1117. ABSTRACT | FULL TEXT   Obesity Yanovski and Yanovski NEJM 2002;346:591-602. FULL TEXT   Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications Franz et al. Diabetes Care 2002;25:148-198. FULL TEXT   Extracts from ""Clinical Evidence"": Obesity Arterburn and Noel BMJ 2001;322:1406-1409. FULL TEXT   Targeted Advertising in Medical Journals Clemenson and Bowman Arch Fam Med 2000;9:791-791. FULL TEXT   Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults Heymsfield et al. Arch Intern Med 2000;160:1321-1326. ABSTRACT | FULL TEXT   HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP   © 2000 American Medical Association. All Rights Reserved.